Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis

Next Previous
Trial Profile

Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anidulafungin (Primary) ; Fluconazole; Voriconazole
  • Indications Candidaemia; Invasive candidiasis
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
  • 19 Mar 2020 Results (N=163) pharmacokinetic of Anidulafungin in pooled population analysis from 4 studies, published in the Clinical Pharmacology and Therapeutics
  • 06 Jul 2019 Results of post hoc pooled analysis determining the efficacy and safety of anidulafungin treatment in patients with intra abdominal candidiasis from five prospective studies (NCT00496197, NCT00548262, NCT00537329,NCT00689338 and NCT00805740) published in the European Journal of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top